Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ANAnixa Biosciences, Inc. logo

Anixa Biosciences, Inc. (ANIX)

NASDAQ Capital Market · Currency in USD
$2.99 ▲ +0.21 (+7.55%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.02 ▲ +0.03 (+0.84%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$2.78
Open
$2.80
Day's Range
$2.80 – $3.14
52 Week Range
$2.32 – $5.46
Volume
326,677
Avg. Volume
295,055
Market Cap
$103.94M
Beta (5Y Monthly)
0.60
PE Ratio (TTM)
--
EPS (TTM)
-$0.30
Earnings Date
Jan 11, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.00

Profile: Anixa Biosciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4
CEO
Amit Kumar
Website
anixa.com

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment.

Earnings

Next report: Mon, Jan 11, 2027
EPS estimate -$0.08
DateEst.Actual
Sep 9, 2026-$0.08-$0.08Beat
Jun 10, 2026-$0.10-$0.07Beat
Mar 9, 2026-$0.09-$0.08Beat
Jan 12, 2026-$0.09-$0.09Miss
Sep 10, 2025-$0.10-$0.07Beat
May 28, 2025-$0.10-$0.09Beat

Analyst view

Consensus price target
$6.00 ▲ +100.7%
Range $6.00 – $6.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ANIX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.